Durvalumab continues to demonstrate efficacy in a variety of cancers, with new data from the phase 3 MATTERHORN trial solidifying its use with chemotherapy in gastric cancer.
Clostridioides difficile (C difficile) represents a serious public health threat, with pharmacists and advocacy organizations playing critical roles in prevention, education, and management.